Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer

Since pharmacokinetics in patients undergoing hemodialysis differs from that in patients with normal renal function, chemotherapy for a hemodialysis patient should be considered with due care. We administered chemotherapy of modified FOLFOX6 to a patient on hemodialysis with inoperable metastatic co...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 35; no. 4; p. 673
Main Authors Matoba, Shuichiro, Sawada, Toshihito, Toda, Shigeo, Moriyama, Jin, Yokoyama, Tsuyoshi, Ehara, Kazuhisa, Mine, Shinji, Ueno, Masaki, Kinoshita, Yoshihiro, Matsuda, Masamichi, Tsutsumi, Kenji, Hashimoto, Masaji, Udagawa, Harushi, Watanabe, Goro, Katori, Hideyuki, Hayashi, Masahiro, Igarashi, Masahiro, Ito, Tadaaki, Hasebe, Shinobu, Sato, Mayumi
Format Journal Article
LanguageJapanese
Published Japan 01.04.2008
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Colorectal Neoplasms - complications
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Female
Fluorouracil - therapeutic use
Humans
Leucovorin - therapeutic use
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Middle Aged
Nephrosis - complications
Nephrosis - therapy
Organoplatinum Compounds - therapeutic use
Renal Dialysis
Online AccessGet more information

Cover

More Information
Summary:Since pharmacokinetics in patients undergoing hemodialysis differs from that in patients with normal renal function, chemotherapy for a hemodialysis patient should be considered with due care. We administered chemotherapy of modified FOLFOX6 to a patient on hemodialysis with inoperable metastatic colorectal cancer, and measured his plasma concentration of total platinum and non-protein-bound platinum. Since there is no reported case of oxaliplatin use in patients on hemodialysis so far, we evaluated whether it could be safely used for such patients. We made a dose escalation study with 40, 50, 60, 70 and 85 mg of oxaliplatin, and evaluated the pharmacokinetics at each dose. AUC was 5.67-10.21 mg/L x h. The dialysis removal rate was 84.0%. Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases.
ISSN:0385-0684